<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>25(1)</volume><submitter>Abu Hamdeh N</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Multiple myeloma (MM) substantially impairs health-related quality of life (QoL). Evidence from low- and middle-income countries is limited, and identifying reliable predictors of QoL is essential to guide supportive care strategies.&lt;h4>Methods&lt;/h4>We conducted a multicenter cross-sectional study of 202 MM patients from six hospitals in the West Bank, Palestine (2018-2025). Patients completed the validated Arabic EORTC QLQ-MY20 questionnaire. Clinical, demographic, and therapeutic variables were collected, and predictors of QoL subscales were analyzed using non-parametric tests and multivariable linear regression with LASSO variable selection.&lt;h4>Results&lt;/h4>In the Side Effects of Treatment subscale, abdominal pain (β = 6.75; 95% CI: 1.92-11.59; p = 0.006), chest pain (β</pubmed_abstract><journal>BMC cancer</journal><pagination>1472</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12487296</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Predictors of quality of life in multiple myeloma patients: a multi-centered cross-sectional study.</pubmed_title><pmcid>PMC12487296</pmcid><pubmed_authors>Shaheen L</pubmed_authors><pubmed_authors>Ihmoud F</pubmed_authors><pubmed_authors>Alawna A</pubmed_authors><pubmed_authors>Abdul-Hafez HA</pubmed_authors><pubmed_authors>Abu Khadija H</pubmed_authors><pubmed_authors>Atallah S</pubmed_authors><pubmed_authors>Dweikat OAA</pubmed_authors><pubmed_authors>Khaleel A</pubmed_authors><pubmed_authors>Salloum O</pubmed_authors><pubmed_authors>Abu Hamdeh N</pubmed_authors><pubmed_authors>Zahran A</pubmed_authors><pubmed_authors>Ahmad MM</pubmed_authors><pubmed_authors>Yaghmour R</pubmed_authors><pubmed_authors>Riyad N</pubmed_authors><pubmed_authors>Barq A</pubmed_authors><pubmed_authors>AbuAlrub I</pubmed_authors><pubmed_authors>Bali B</pubmed_authors><pubmed_authors>Masu'd M</pubmed_authors><pubmed_authors>Hadya F</pubmed_authors><pubmed_authors>Alnees M</pubmed_authors><pubmed_authors>Salah Q</pubmed_authors><pubmed_authors>Ewidat O</pubmed_authors><pubmed_authors>Zayed A</pubmed_authors><pubmed_authors>Ismail S</pubmed_authors><pubmed_authors>AbuAlsuod E</pubmed_authors><pubmed_authors>Najajra D</pubmed_authors><pubmed_authors>Zraiq S</pubmed_authors><pubmed_authors>Darwish A</pubmed_authors><pubmed_authors>Allaham S</pubmed_authors><pubmed_authors>Marrawani M</pubmed_authors><pubmed_authors>Alzirei K</pubmed_authors></additional><is_claimable>false</is_claimable><name>Predictors of quality of life in multiple myeloma patients: a multi-centered cross-sectional study.</name><description>&lt;h4>Background&lt;/h4>Multiple myeloma (MM) substantially impairs health-related quality of life (QoL). Evidence from low- and middle-income countries is limited, and identifying reliable predictors of QoL is essential to guide supportive care strategies.&lt;h4>Methods&lt;/h4>We conducted a multicenter cross-sectional study of 202 MM patients from six hospitals in the West Bank, Palestine (2018-2025). Patients completed the validated Arabic EORTC QLQ-MY20 questionnaire. Clinical, demographic, and therapeutic variables were collected, and predictors of QoL subscales were analyzed using non-parametric tests and multivariable linear regression with LASSO variable selection.&lt;h4>Results&lt;/h4>In the Side Effects of Treatment subscale, abdominal pain (β = 6.75; 95% CI: 1.92-11.59; p = 0.006), chest pain (β</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Sep</publication><modification>2026-06-04T01:23:06.088Z</modification><creation>2026-05-03T03:14:03.372Z</creation></dates><accession>S-EPMC12487296</accession><cross_references><pubmed>41029258</pubmed><doi>10.1186/s12885-025-14960-w</doi></cross_references></HashMap>